Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enhanced ozone strongly reduces carbon sink strength of adult beech (Fagus sylvatica)--resume from the free-air fumigation study at Kranzberg Forest.
Matyssek R, Wieser G, Ceulemans R, Rennenberg H, Pretzsch H, Haberer K, Löw M, Nunn AJ, Werner H, Wipfler P, Osswald W, Nikolova P, Hanke DE, Kraigher H, Tausz M, Bahnweg G, Kitao M, Dieler J, Sandermann H, Herbinger K, Grebenc T, Blumenröther M, Deckmyn G, Grams TE, Heerdt C, Leuchner M, Fabian P, Häberle KH. Matyssek R, et al. Among authors: wipfler p. Environ Pollut. 2010 Aug;158(8):2527-32. doi: 10.1016/j.envpol.2010.05.009. Epub 2010 Jun 8. Environ Pollut. 2010. PMID: 20570421
Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcome.
Bsteh G, Hoepner R, Gernert JA, Berek K, Gradl C, Kliushnikova D, Damulina A, Traxler G, Föttinger F, Habernig S, Krajnc N, Betancourt AXL, Ponleitner M, Zrzavy T, Deisenhammer F, Di Pauli F, Havla J, Khalil M, Kümpfel T, Wipfler P, Chan A, Berger T, Hammer H, Hegen H. Bsteh G, et al. Among authors: wipfler p. Eur J Neurol. 2025 Jan;32(1):e16587. doi: 10.1111/ene.16587. Eur J Neurol. 2025. PMID: 39686558 Free PMC article.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
Beyond T cell toxicity - Intrathecal chemokine CXCL13 indicating B cell involvement in immune-related adverse events following checkpoint inhibition: A two-case series and literature review.
Otto F, Seiberl M, Bieler L, Moser T, Kleindienst W, Wallner-Essl W, Koelblinger P, Wipfler P, Harrer A. Otto F, et al. Among authors: wipfler p. Eur J Neurol. 2024 Jul;31(7):e16279. doi: 10.1111/ene.16279. Epub 2024 Mar 31. Eur J Neurol. 2024. PMID: 38556899 Free PMC article.
59 results